Hjem › Burkitts lymfom › New York › New York City

Kliniske studier for Burkitts lymfom i New York City, NY

13 studier for Burkitts lymfom søker deltakere på steder i og rundt New York City (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.

Offisiell studietekst (engelsk)

Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

RekruttererFase 3

Memorial Sloan Kettering Cancer Center, New York

Alder 1 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT07223021

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

RekruttererFase 2

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
og 1 flere

366 Days – 46 Years · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

RekruttererFase 3

Mount Sinai Hospital, New York
NYP/Weill Cornell Medical Center, New York

Alder 18 til 39 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT03150693

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

RekruttererFase 2

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Memorial Sloan Kettering Cancer Center, New York
NYP/Weill Cornell Medical Center, New York

365 Days · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

RekruttererFase 3

David H. Koch Center for Cancer Care, New York

Alder 18 og eldre · Alle kjønn · Oppdatert 21. sep. 2026 · NCT07648264

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

RekruttererFase 1/2

Memorial Sloan Kettering Cancer Center ( Site 1010), New York

6 Months – 25 Years · Alle kjønn · Oppdatert 17. sep. 2026 · NCT06395103

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

RekruttererFase 1

Columbia University Irving Medical Center/New York Presbyterian Hospital, New York

Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT03666000

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

RekruttererFase 2

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
NYP/Weill Cornell Medical Center, New York

Alder 1 til 30 · Alle kjønn · Oppdatert 1. sep. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

RekruttererFase 3

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Mount Sinai Hospital, New York
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
og 2 flere

365 Days – 25 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT03959085